Study title: Clinical Study of FEIBA (S-TIM 4), IMMUNO relative of Liver Enzymes SGOT, SGPT, Y-GT and LDH, HIV-Antibody, Hepatitis B- and C-Antibodies, as well as Objective and Subjective Adverse Events
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Hemic and Lymphatic Diseases [C15] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: FACTOR VIII INHIBITOR BYPASSING ACT | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |